In the K-ras wild-type pancreatic cancer cases, although in less than 10% of the cases, the mTOR inhibitors may have potential therapeutic importance since they often harbor RAS-MAPK pathway-activating alterations and elevated phosphorylation mTOR pathway proteins [38]. The gene discussed is MTOR; the disease is familial pancreatic carcinoma.